ADVATE Hemophilia A Outcome Database

Trial Profile

ADVATE Hemophilia A Outcome Database

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Rurioctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AHEAD
  • Sponsors Baxalta; Baxter Healthcare Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Interim results of 3 year follow-up of patients with severe and moderate Hemophilia A (n=522) enrolled in the AHEAD study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 Oct 2015 Planned number of patients changed from 350 to 500, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top